NCT05834543 - Clinical Trial to Evaluate the Safety and Effectiveness of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 26, 2023

Primary Completion Date

October 23, 2024

Study Completion Date

March 3, 2025

Conditions

Advanced Esophageal Squamous Cell Carcinoma

Interventions

DRUG

TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin

"TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."

DRUG

Penpulimab injection, Paclitaxel, Cisplatin

"Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).~Paclitaxel and Cisplatin are chemotherapy."

DRUG

TQB2618 injection, Penpulimab injection, TQB3617capsules

TQB2618 injection：Anti-TIM-3 monoclonal antibody. Penpulimab injection：Humanized Monoclonal Antibody to Programmed Cell Death Protein 1 (PD-1).

Trial Locations (10)

241000

The First Affiliated Hospital of Wannan Medical College, Wuhu

244099

Tongling People's Hospital, Tongling

272007

Affiliated Hospital of Jining Medical College, Jining

450000

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

455000

AnYang Tumor Hospital, Anyang

463003

Zhumadian Central Hospital, Zhumadian

471003

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

046000

Changzhi People's Hospital, Changzhi

Heping Hospital Affiliated to Changzhi Medical College, Changzhi

048000

Jincheng General Hospital, Jincheng